Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;17(4):372-379.
doi: 10.1176/appi.focus.20190024. Epub 2019 Nov 6.

Clinician Liability in Prescribing Antidepressants

Affiliations

Clinician Liability in Prescribing Antidepressants

Deborah Giorgi-Guarnieri. Focus (Am Psychiatr Publ). 2019 Oct.

Abstract

Malpractice claims frequently focus on the clinician's prescription of medications. Claims may arise in many environments: inpatient units, outpatient offices, prisons, journal articles, pharmaceutical talks, and clinical trials of new medications. The basis of the claim may be product liability, informed consent, deliberate indifference, violation of the Federal Food, Drug, and Cosmetic Act, or academic malpractice. All malpractice claims include a duty, a breach of duty, causation, and damages. The duty and breach of duty may be obvious, but causation can vary considerably in malpractice claims. Perhaps the damages are most apparent when the patient has suffered side effects. This article explores clinician liability for the use of antidepressants from the clinical trial to the removal from the market.

Keywords: antidepressants; ethics complaints; liability; malpractice.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schachtman NA: Drug-Induced Birth Defects Exploring the Intersection of Regulation, Medicine, Science, and Law—An Educational Module (2016). Washington, DC, National Academies of Science, Engineering, and Medicine, 2016
    1. Amsterdam JD, McHenry LB, Juriedini JN: Industry-corrupted psychiatric trials. Psychiatr Pol 2017; 51:993–1008 - PubMed
    1. Nemeroff CB, Evans DL, Gyulai L, et al. : Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158:906–912 - PubMed
    1. Amsterdam JD, McHenry LB: The paroxetine 352 bipolar trial: a study in medical ghostwriting. Int J Risk Saf Med 2012; 24:221–231 - PubMed
    1. Complaint of Scientific Misconduct Against Dwight L. Evans, Laszlo Gyulai, Charles Nemeroff, Gary S. Sachs, and Charles L. Bowden. July 8, 2011. http://psychrights.org/research/Digest/Science4Sale/110708EthicsComplain...

LinkOut - more resources